African Americans and Men Who Have Sex with Men Are Groups Most Affected by HIV

New Centers for Disease Control and Prevention (CDC) estimates of HIV prevalence in the United States indicate that between 1,039,000 and 1,185,000 people were living with HIV in December 2003.  The estimates provide the clearest picture to date of the scope of the U.S. epidemic overall and among specific racial and ethnic and risk groups.

The new estimates indicate that HIV continues to have the greatest impact among African Americans and MSM.  At the end of 2003, blacks accounted for 47 percent of people estimated to be living with HIV in the U.S.; whites accounted for 34 percent and Hispanics for 17 percent.  Asian/Pacific Islanders and American Indians/Alaska Natives each represented roughly
1 percent of the HIV-positive population. 

By transmission category, MSM remained the most heavily affected group, accounting for 45 percent of people living with HIV.  Individuals infected through high-risk heterosexual contact comprised 27 percent, and those infected through injection drug use accounted for 22 percent of the HIV-positive population.  Roughly three-quarters (74%) of Americans estimated to be living with HIV are male. 

The study suggests that the make-up of the HIV-positive population may begin to shift in coming years, as non-Hispanic blacks, females, and individuals infected through high-risk heterosexual contact account for a higher proportion of infections among people living with HIV (not AIDS) than among those already living with AIDS.

The last estimate of HIV prevalence, released in 2002, suggested that at the end of 2000, between 850,000 and 950,000 people were living with HIV.  These estimates, however, did not include breakdowns by racial and ethnic or risk groups.  Besides updating the prevalence estimates, researchers also examined the proportion of the HIV-positive population aware of their infection status. 

Results indicate that as of 2003, between 24 and 27 percent of individuals living with HIV infection remained undiagnosed.  As improved treatments have increased the lifespan of HIV-positive persons in recent years, overall prevalence has steadily increased in the U.S. (Presentation T1-B1101).

A separate CDC analysis suggests that undiagnosed HIV infection continues to play a significant role in the extremely high rates of infection among African-American MSM.  Consistent with earlier research, black MSM in a new five-city study were more than twice as likely to be infected with HIV as other MSM, and were less likely to be aware of their infection.  Forty-six percent of black MSM in the study were HIV-positive, compared to 21 percent of white MSM and 17 percent of Hispanic MSM. 

Among HIV-infected MSM, 67 percent of black men, 48 percent of Hispanic men, and 18 percent of white men were unaware of their infection before study participation, underscoring the need to reach MSM with testing and prevention services. The study surveyed 1,767 MSM over age 18 at public venues in Baltimore, Los Angeles, Miami, New York City, and San Francisco between June 2004 and April 2005 (Plenary session, “New Approaches to Tracking the HIV Epidemic in the U.S.”). 

Other CDC data point to the continuing impact of HIV on young African-American MSM across the nation.  Researchers examined trends in new HIV diagnoses (with or without AIDS) among persons 13 to 24 years of age between 1994 and 2003 in 25 U.S. states with longstanding, name-based HIV reporting. 

Results indicate that new diagnoses declined significantly among young women, but rose among young men.  Among 13- to 24-year-old females, new HIV diagnoses fell 20 percent over the 10-year period.  HIV diagnoses also declined among young men for the first few years of the period (by 30% from 1994 to 1998); but the decline was offset by a 41 percent increase from 1999 to 2003.  The increase among young men was driven by a 47 percent rise in diagnoses among MSM ages 20-24, 60 percent of whom were black. 

While researchers were unable to determine if the increases in HIV diagnoses among young men were the result of increased testing or an actual increase in new infections, the findings are consistent with other recent data suggesting a possible resurgence of HIV among young MSM (Presentation M1-B0802).

“These new data underscore the need to deploy the full spectrum of HIV prevention strategies to confront today’s epidemic,” said Dr. Ronald O. Valdiserri, co-chair of the 2005 National HIV Prevention Conference and deputy director of CDC’s HIV, STD and TB prevention programs.  “HIV-positive individuals are living longer than ever before, and we must reach them with services that can help them stay healthy and protect others from infection.  Reaching at-risk populations with HIV testing and providing infected and at-risk individuals with effective, ongoing prevention services will be critical to reduce the number of new infections.”

06/15/05

Source
US Centers for Disease Control and Prevention (CDC).

 

 





 

 

HIV/AIDS Topics
 [ A to Z ]

Abacavir Sensitivity Reaction
Acquired Drug Resistance
Acquired Rectal Fistula

Adherence
Adolescents
African Americans
Age/aging
AIDS-defining Illnesses
AIDS-related Non-Hodgkin's Lymphoma
Alcohol
Alternative Therapies
ALT/AST
Anal Intraepithelial Neoplasia (AIN)
Anemia / Fatigue
Antimycobacterial Prophylaxis
Atheroschlerosis
Aspergillosis
Autoimmune Thyroid Disease
Bacteremia
Bacterial Infections
Bartonella
Body Mass Index (BMI)
Bone Disorders
Boosted Protease Inhibitors
Breast-feeding
Buffalo Hump (BH)
Caesarean section
Candidiasis
Cancers
Cardiovascular Disease
CXCR4 Co-receptor
CCR5 Co-receptor
CD4 T Cell Count/ Percent
CD4+ and CD8 in Whole Blood
CD8+ T Cell
CD8 and CD3 Cells
Cerebrospinal Fluid (CSF)
Cholesterol / Triglycerides
Children and Infants
Central Nervous System (CNS)
Clinical Trials
CMV Retinitis
Complementary Alternative Therapies
Cosmetic Procedures
CYP3A Pathway
Cryptococcus
Cytomegalovirus
Dementia
Depression
Developing Countries
Diabetes
Diarrhea / Gastrointestinal
Dietary Intake
Directly Observed Therapy (DOT)
Disease Progression
Dosing
Drug Abuse
Drug Interactions
Drug Pricing
Drug Resistance Testing
Dyslipidemias
Elevated bilirubin and Jaundice
Elevated Creatinine Level
Entry Inhibitors
Epstein Barr Virus
Epidemiology
Eradication (HIV)
Ethnicity
Experimental Drugs
Experimental Vaccine
Facial Implants
Fat Loss
Fat Accumulation
Fat Redistribution
FDA-Approved Treatments
Fixed-dose Combinations (FDC)
Flu / Fever
Fungal Infections
Fusion or Entry Inhibitors
GB Virus C (GBC of hepatitis G)
Gender
Generics
Genetics
Genotype Resistance Testing
Glucose MetabolismInsulin Resistance
Growth Failure
Growth Hormone
Guidelines
Gynecomastia
HAART / Mega-HAART
Hairy leukoplakia
Hepatotoxicity (Liver Toxicity)
Hispanic Ethnicity
Histoplasmosis
HIV Antibody
HIV Eradication
HIV Prevalence
HIV Proviral DNA Testing
HIV p24 Antigen
HIV-related Adverse Events
HIV Replication
HIV RNA and HIV bDNA Testing
HIV Therapeutics
HIV-1 Fitness Assay
Hodgkin's Disease
Hormone Therapies
Hospice Care
Human Herpesvirus 8 (HHV-8)
Humanpapillomavirus (HPV)
Hydroxyurea (HU)
Hyperlactatemia
Hyperlipidemia
Hypersusceptibility
Hyperbilirubinemia / Jaundice
Hypertension
Hypophosphatemia
Hypothyroidism
Immunotherapy
Immune Based Therapy
Immunosuppression
Immune Restoration Disease
Immune Reconstitution Disease (IRD)
Immune Reconstitution Inflammatory Syndrome (IRIS)
Infants
Infective Endocarditis
Injection Site Reactions
Insulin Resistance
Intensification Therapy
Injection Drug Users (IDU)
Integrase Inhibitors
JC Virus
Kaposi sarcoma
Kidney Toxicity / Failure
Kinetic PCR
Lactic Acidosis/Hyperlactatemia
Liver Enzyme
Kaposi's Sarcoma
Leukoencephalopathy
Lipid Abnormalties
Long-term Non Progression
Lung Diseases
Non-Tuberculosis Lung Diseases
Malignancies
Mega-HAART
Men Who Have Sex with Men (MSM)
Meningoencephalitis
Microbicides
Miscellaneous
Mitochondrial Toxicity
Mortality and Morbidity
Mother-to-Child Transmission
Multidrug Resistant (MDR) HIV
Mutation Resistance
Myalgias (muscle aches)
Mycobacterium avium Complex
Myelopathy
Myocardial Infarction (MI)
Natural History
NAMs
(nucleoside-associated resistance mutations)

Nausea
Neonatal Transmission
Nephrotoxicity
Neopterin
Neurotoxicity
Neutropenia
Nevirapine-associated Rash
Nitazoxanide
Nucleic Acid Screening Test
Non-AIDS Related Hodgkin's Lymphoma
Non-Tuberculosis Lung Diseases
Non-Nucleoside Reverse Transcriptase Inhibitors (nNRTIs)
Non-occupational Post Eexposure Prophylaxis (NPEP)
NNRTI Toxicities and Side Effects Guide
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Nucleotide Reverse Transcriptase Inhibitors (NtRTIs)
Nutrition
Opportunistic Infections (OIs)
Oral OIs/ hairy leukoplakia/ warts
Pain
Palliative Care
Pancreatitis
Parasites
Pathogenesis

Pediatrics
Peripheral Neuropathy
Perinatal Transmission
Pharmacokinetics

Pharmacodynamics
Pneumonia
Pneumocystis carinii pneumonia (PCP)
Phenotype Resistance Testing
Pharmacokinetics
Progressive Multifocal Leukoencephalopathy (PML)
Pheumonia
Physical Exercise
Positron Emission Topography
Protease Assay
Proteinuria and Elevated Creatinine Level
Psychiatric (mental)
PML
Post Exposure Prophylaxis (PEP)

Post-traumatic Stress Disorder (PTSD)
Pregnancy
Prevention
Primary HIV Infection
Protease Inhibitors (PIs) / Boosted PIs
Protease Inhibitor Toxicities/Side Effects (PDF)
Public Policy
Quality of Life

Race / Ethnicity
real-time DNA PCR (RT DNA-PCR)
Renal (Kidney) Toxicity / Failure
Replication Capacity Tests
Resistance
Resistance Mutation
Resistance Testing
Resistance Training
Ritonaivr Boosted PIs
Safer Sex
Salvage Therapies
Seroconversion
Severe Adverse Drug Reactions
Sexual Dysfunction
Sexually Transmitted Diseases
Side Effects
Simplification Regimens/Trials
Skin Conditions
Smoking
Staphylococcus Aureus
Steroids
Stroke
Substance Abuse
Suicidal Ideation
Survival
Super Infection
Sustained Virological Response
Syphilis
Switch Studies
TAMs (thymidine analogue mutations)
Tat gene
Testosterone
thrombosis
Therapeutic Drug Monitoring (TDM)
Therapeutic HIV Vaccines
Thyroid Disease
Toxicities and Side Effects
Toxicities Guides
Toxoplasmosis
Transmission

Transplantation
Treatment Failure
Treatment Guidelines
Treatment Interruptions (TIs)
Tuberculosis
Undetectable HIV Viral Load
Unsafe Sex
Vaccines
Vaginal HIV Shedding
Vertical Transmission of HIV
Viral (HIV) Set Point
Viral Load (HIV RNA or HIV bDNA)
Viral Load Rebound / Increase
Virco Antivirogram
Virologic Control
Virologic Failure
Visceral Adiposity
Virtual Phenotype Resistance Testing
Wasting - HIV
White Race / Caucasian
Women